BBT 207
Alternative Names: BBT-207Latest Information Update: 12 Jan 2024
Price :
$50 *
At a glance
- Originator Bridge Biotherapeutics
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 11 Oct 2023 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05920135)
- 11 Sep 2023 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in South Korea (PO) (NCT05920135)
- 23 Apr 2023 Bridge Biotherapeutics plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease) in the USA and South Korea (PO)